Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems

TNDM 01.07.2025

Full Press ReleaseSEC FilingsOur TNDM Tweets

About Gravity Analytica

Recent News

  • 02.26.2025 - Tandem Diabetes Care Q4 2024 Earnings
  • 01.15.2025 - Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
  • 01.07.2025 - Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems

Recent Filings

  • 12.18.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.21.2024 - 144 Report of proposed sale of securities
PDF Version

SAN DIEGO--(BUSINESS WIRE)--Jan. 7, 2025--Tandem Diabetes Care, Inc.(Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collaboration agreement with the University ofVirginia Center for Diabetes Technology(UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems.

The research collaboration will rely on the UVA Center for Diabetes Technology’s groundbreaking work to improve care for patients with diabetes through technology-based interventions, and its successes in translating advanced automated insulin delivery (AID) algorithms into medical devices used around the world, as well as Tandem’s market leading expertise in insulin delivery devices, algorithm implementation, and data management.

The collaboration will expand on Tandem’s ongoing research into the advancement of automated closed-loop insulin delivery technology, and will involve scientists, clinicians, and functional experts from both institutions. Results from this collaboration may lead to clinical research to accelerate approved uses for Tandem’s next-generation AID systems.

“Our past work with UVA, including research related to our automated insulin delivery systems as part of theInternational Diabetes Closed Looptrials, helped contribute to life-changing products for the diabetes community,” saidJohn Sheridan, president and chief executive officer at Tandem. “We believe this research collaboration will continue on our joint history of delivering new innovations that can further improve the lives of people living with diabetes.”

“After more than 10 years working with the Tandem team, this is an exciting new beginning for our collaboration to serve patients with diabetes,” saidMarc Breton, PhD, associate director for research at theUVA Center for Diabetes Technology. “Together, we will expand our research efforts into automated insulin delivery with the goal of once more substantially enhancing care and quality of life for patients around the world.”

Tandem will provide research funding, technology, and supplies to theUniversity of Virginiaduring the agreement term for diabetes-centered research and potential clinical studies.

AboutTandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology.Tandem Diabetes Careis based inSan Diego, California. For more information, visittandemdiabetes.com.

FollowTandem Diabetes Careon X @tandemdiabetes; use #tslimX2 #TandemMobi and #TandemDiabetes.FollowTandem Diabetes Careon Facebook atwww.facebook.com/TandemDiabetes.FollowTandem Diabetes Careon LinkedIn atlinkedin.com/company/tandemdiabetes.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things: (i) the multi-year collaboration agreement to advance research and development efforts on fully automated closed-loop systems; (ii) that the collaboration will expand upon Tandem’s ongoing research into advancing automated insulin delivery technology; (iii) that the results from this collaboration may lead to clinical research that accelerates approved uses for Tandem’s next-generation AID systems; (iv) that the collaboration will deliver new innovations that can further improve the lives and/or enhance the care of people living with diabetes; and (v) that Tandem will provide research funding, technology and supplies that will fund diabetes-centered research and potential clinical studies. These statements are subject to numerous risks and uncertainties associated with developing new products generally, including possible delays in the Company’s product development programs and/or clinical trials, possible future actions of the FDA or any other regulatory body or governmental authority, including the potential that the FDA may not agree with Tandem’s proposed pathway for regulatory approval; the potential that the collaboration agreement could be terminated; the potential that other products or technological breakthroughs for the treatment of diabetes could make Tandem’s products obsolete or less desirable. These and other risks are identified and described in greater detail under the “Risk Factors” heading of our most recent Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors.

© 2025 All rights reserved.Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks ofTandem Diabetes Care, Inc.inthe United Statesand/or other countries. All third-party marks are the property of their respective owners.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250107162995/en/

Media Contact:858-255-6388Media@tandemdiabetes.comInvestor Contact:858-366-6900IR@tandemdiabetes.com

Source:Tandem Diabetes Care, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com